Current Research Studies
Dermatitis - ARCADIA Study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
Condition or Therapy:
Moderate-to-severe atopic dermatitis
What is the goal of this study?
70% of people who suffer from atopic dermatitis have moderate-to-severe atopic dermatitis.
The ARCADIA study is testing the effectiveness of an investigational medication called Nemolizumab to reduce the symptoms of moderate-to-severe atopic dermatitis in adolescents and adults. The study will recruit approximately 750 people through North America, Asia-Pacific and Europe who have been living with moderate-to-severe atopic dermatitis and itching for at least 2 years.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 12 years or older at the time of the screening visit
- Have a diagnosis of moderate-to-severe atopic dermatitis for at least 2 years
- Have had an inadequate response to topical medications
What will happen if my child takes part in this study?
Study participants will visit Seattle Children's approximately 16 times over the course of 52 weeks.
In the first 16 weeks, participants will be randomly assigned (like drawing straws) to receive either Nemolizumab or a placebo. Both Nemolizumab and the placebo will be administered by injections (shots) under the skin (subcutaneous injection). After the 16 weeks, participants will be given the study drug until the end of the study.
Safety will be monitored using surveys/questionnaires, exams performed by the study doctors and blood tests.
For additional information, visit the Arcadia Study webpage.
Who can I contact for more information?
To learn more, call 206-987-5402 or email the study coordinator.